ADAM22

Across TCGA pan-cancer cohorts, ADAM22 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of ADAM22’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ADAM22 RNA is repressed in tumor relative to normal tissue. In most cancer types ADAM22 is over-expressed in tumor, although a few such as THCA and UCEC show the opposite, repressed pattern.

THCA, UCEC, and LIHC are the cancer types where ADAM22 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADAM22 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−2.302	<.001	11	view →
UCEC	All	All	−1.464	<.001	6	view →
LIHC	All	II,III,IV	+0.435	<.001	6	view →
BRCA	All	All	−0.379	<.001	6	view →
KICH	Female	All	−1.088	<.001	5	view →
CHOL	All	All	+0.907	<.001	4	view →
KIRP	Male	All	−0.740	<.001	2	view →
STAD	Male	II,III,IV	+0.352	.038	1	view →
KIRC	All	II,III,IV	−0.340	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

ADAM22–THCA

Open the THCA breakdown →